News

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).

New TransUnion analysis explores millennial healthcare payment behavior.

Overprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.

As 2017 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.

Simple strategies can improve the nutritional well-being of COPD patients and help them maintain their weight.

From identifying must-read books to exploring how policy changes will affect the industry, Managed Healthcare Executive's most popular articles this year shed light on the biggest areas of interest to managed care organizations.

A Walgreens study sheds light on the benefits of patient-centered pharmacy-based programs.

Insiders unmask what policy actions will continue and what will develop in the next year.

FDA okays the first short-acting insulin approved as a “follow-on” product.

Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.

The Innovation and Value Initiative's Mark Linthicum talks to Managed Healthcare Executive (MHE) a new tool to better measure value in healthcare treatments.

The Innovation and Value Initiative launched the Open-Source Value Project, creating tools that help payers, providers, and healthcare systems make informed and patient-centered decisions that produce better health outcomes.

A new study reveals interesting findings about improving the health of pediatric asthma patients and integrated care programs.

While breastfeeding has been thought to decrease children’s risk of developing allergies and asthma, a new study counters that belief.

A new study reveals an important spillover effect of parental Medicaid coverage.

One expert says the interoperability of medical devices, especially of IoT medical devices, creates soft spots in an organization’s security framework.

A sneak peek at the findings from our 2018 Technology Survey reveal where healthcare organizations are struggling most when it comes to interoperability and Big Data.

FDA recently approved a new diabetes medication, as well as a drug to treat severe asthma.

Fitbit devices will be used for an NIH research program to explore the influence of behavioral, biological, and environmental influences on health.

The regulatory landscape for interoperability is changing, according to Mildred Segura, partner at international law firm Reed Smith.

If signed into law, Trump’s tax reform will have substantive impacts on healthcare organizations and on individuals.

Two new studies address the financial implications of unexpected major healthcare expenses for common cardiovascular conditions and procedures.

The American Medical Informatics Associations says interoperability has fallen off as a priority at the ONC. Here are its top recommendations to the organization.

The COPD executive care team at Sanford Medical Center is leading to impressive results. Find out who is part of the team and how it works.

Soon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).

Healthcare executives have a unique leadership role to play in addressing the opioid crisis. Here’s what you need to do now.

A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.

A new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.

Experts weigh in on the findings from Managed Healtcare Executive’s 2017 State of the Industry Survey.